{Reference Type}: Journal Article
{Title}: Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023-January 2024.
{Author}: Paireau J;Durand C;Raimbault S;Cazaubon J;Mortamet G;Viriot D;Milesi C;Daudens-Vaysse E;Ploin D;Tessier S;Vanel N;Chappert JL;Levieux K;Ollivier R;Daoudi J;Coignard B;Leteurtre S;Parent-du-Châtelet I;Vaux S;
{Journal}: Influenza Other Respir Viruses
{Volume}: 18
{Issue}: 6
{Year}: 2024 Jun
{Factor}: 5.606
{DOI}: 10.1111/irv.13311
{Abstract}: In September 2023, France was one of the first countries that started a national immunisation campaign with nirsevimab, a new monoclonal antibody against respiratory syncytial virus (RSV). Using data from a network of paediatric intensive care units (PICUs), we aimed to estimate nirsevimab effectiveness against severe cases of RSV bronchiolitis in France. We conducted a case-control study based on the test-negative design and included 288 infants reported by 20 PICUs. We estimated nirsevimab effectiveness at 75.9% (48.5-88.7) in the main analysis and 80.6% (61.6-90.3) and 80.4% (61.7-89.9) in two sensitivity analyses. These real-world estimates confirmed the efficacy observed in clinical studies.